

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1

(43) International Publication Date
19 September 2002 (19.09.2002)

PCT (10) International Publication Number
WO 02/073187 A1

(51) International Patent Classification: G01N 33/00,
A01K 67/00, 67/033, 67/027, C12N 5/00, 5/02, 15/00,
15/09, 15/63, 15/70, 15/74, 15/85, 15/87

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/07109

(22) International Filing Date: 11 March 2002 (11.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Date: 60/274,216 9 March 2001 (09.03.2001) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **ADVANCED CELL TECHNOLOGY, INC.** [US/US]; One Innovation Drive, Worcester, MA 01650 (US).

Published:
— *with international search report*

(72) Inventor; and

(75) **Inventor/Applicant (for US only):** LANZA, Robert
[US/US]; 25 South Meadow Road, Clinton, MA 01510
(US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: TESKIN, Robin, L. et al.; Pillsbury Winthrop LLP, 1600 Tysons Boulevard, McLean, VA 22102 (US).

(54) Title: METHOD FOR GENERATING REPLACEMENT CELLS AND/OR TISSUES

(57) Abstract: Disclosed are methods of isolating differentiated cells or adult stem cells from pluripotent cells and particularly ICM cells, by exposing such pluripotent cells to environmental cues in order to encourage development along a certain path.

WO 02/073187 A1

WO 02/073187

PCT/US02/07109

Method for Generating Replacement Cells and/or Tissues

Related Applications

[0001] This application claims benefit of priority to U.S. Serial No. 60/274,216 filed on March 9, 2001 and of which are incorporated by reference in their entirety herein.

Field of Invention

[0002] The present invention is concerned with engineering replacement cells and tissues that may be used for transplantation into patients in need of such tissues. In particular, the present invention provides a means for producing isogenic replacement tissues using nuclear transfer, without requiring *in vitro* isolation and differentiation of embryonic stem cells.

Background of the Invention

[0003] Embryonic stem (ES) cell technology is one of the few known means for generating large numbers of replacement cell types from pre-implantation stage embryos. Nuclear transfer technology in particular enables the isolation of ES and inner cell mass (ICM) cells from a differentiated somatic cell nuclear donor. This technology provides great promise for engineering cells and tissues for human transplantation, because such tissues can be designed using the patient's own cells as the source of nuclear DNA, thereby avoiding the problems of transplant rejection and graft versus host reactions associated with transplanting allogeneic and xenogeneic tissues.

[0004] Despite the promise of this technology, many years of research may still be required before biologists understand how to direct ES cells *in vitro* along a desired line of development in order to generate replacement cells and tissues for human patients. Furthermore, it may be ethically and legally problematic to implant human and/or chimeric human-animal embryos into animals, or to implant human and/or chimeric human-animal ICMs/ES cells into animals that may have the capacity to generate embryos and/or teratomas. Thus, there is an immediate need for methods that enable isolation of

WO 02/073187

PCT/US02/07109

differentiated cells and tissues from ES cells or other pluripotent stem cells that do not require a knowledge of the developmental signals that guide embryonic development, and that do not raise ethical and legal dilemmas with regard to human patients.

[0005] In this regard, researchers have shown using an *in utero* xenotransplantation approach that neural progenitor cells from mice differentiate into cells having glial-like features after injection into the rat forebrain ventricle. See Winkler et al. (June 1998) Incorporation and glial differentiation of mouse EGF-responsive neural progenitor cells after transplantation into the embryonic rat brain, *Mol. Cell. Neurosci.* 11(3): 99-116. Similarly, human neural precursor cells that had been expanded *in vitro* were shown to develop into neurons in a site-specific manner after being transplanted into either an adult or neonatal rat brain. See Fricker et al. (July 1999) Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain, *J. Neurosci.* 19(14): 5990-6005; see also Rosser et al. (July 2000) The morphological development of neurons derived from EGF- and FGF-2-driven human CNS precursors depends on their site of integration in the neonatal rat brain, *Eur. J. Neurosci.* 12(7): 2405-13. In these studies, the resulting neuron cells were not purified but rather were traced by mouse-specific and human-specific markers. Nevertheless, these results suggest that neural progenitor cells respond to host-derived environmental signals that direct their differentiation along multiple phenotypic pathways.

[0006] Researchers from the University of South Florida have recently extended this premise to an *in vitro* setting by showing that it is possible to induce human or mouse bone marrow stromal cells (BMSC), which normally give rise to bone, cartilage, and mesenchymal cells, to differentiate into neuron-like cells by culturing them in the presence of rat fetal mesencephalic or striatal cells. See Sanchez-Ramos et al (August 2000) Adult bone marrow stromal cells differentiate into neural cells *in vitro*, *Exp. Neurol.* 164(2): 247-56. Thus, it may be possible to mimic the environmental signals that induce pluripotent cells to differentiate along a given pathway *in vitro* merely by exposing

WO 02/073187

PCT/US02/07109

pluripotent cells to differentiated cells. However, it is not clear how useful cellular engraftment will be in repairing damaged tissues absent tissue engineering, therefore, differentiated cells derived *in vitro* still have limited utility.

[0007] Furthermore, in order to employ cells that have been environmentally induced to differentiate along a certain developmental path, one must have a means of isolating or purifying such cells away from the inducing cells. This is particularly true where human cells are induced to differentiate in the presence of rat cells or other animal cells that might harbor viruses or other infectious agents that could potentially present a danger to human patients receiving such replacement cells. In this regard, Klug et al have described an approach for isolating relatively pure cardiomyocytes from differentiating murine embryonic stem (ES) cells whereby ES cells are stably transfected with a fusion gene consisting of a selectable marker, aminoglycoside phosphotransferase, linked to the alpha-cardiac myosin heavy chain promoter. See Klug et al (July 1996) Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intercardiac grafts, J. Clin. Invest. 98(1): 216-24; see also McWhir et al (Oct 1996) Selective ablation of differentiated cells permits isolation of embryonic stem cell lines from murine embryos with a nonpermissive genetic background, Nat. Genet. 14(2): 223-8 (using a similar technique to select against differentiated cells). The aminoglycoside phosphotransferase-transfected cells in Klug were differentiated *in vitro* and subjected to G418 selection, and the resulting cardiomyocyte cultures were shown to be highly pure (>99%). Further, stable ES-cell derived cardiomyocyte grafts were observed in the hearts of adult mice seven weeks after implantation. However, as noted by Klug in this report, cellular engraftment has questionable utility in effecting myocardial repair.

[0008] Thus, there is still a need for methods which allow the production and isolation of differentiated cells, adult stem cells and tissues for replacement therapy. Moreover, it would be advantageous to design such replacement cells to genetically match the patient to avoid rejection of the cells and tissues and other harmful immune responses following transplantation into the patient.